Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition
通过抑制介体激酶来预防体内对 PI3K/AKT/mTOR 抑制剂的耐药性
基本信息
- 批准号:10602700
- 负责人:
- 金额:$ 40万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-12 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Antineoplastic AgentsBreast Cancer CellCancer PatientCell LineClinicClinicalClinical TrialsCollaborationsDevelopmentDisease remissionDrug CombinationsDrug ExposureDrug TargetingDrug resistanceEstrogen ReceptorsEstrogen receptor positiveFRAP1 geneFibrinogenFutureGene ExpressionGenetic TranscriptionGoalsGrowthImmunohistochemistryIndividualMCF7 cellMDA-MB-468Malignant NeoplasmsMeasuresMediator of activation proteinModelingMutationNeuroendocrine TumorsPI3K/AKTPTEN genePathway interactionsPatient-derived xenograft models of breast cancerPharmaceutical PreparationsPharmacologic SubstancePhasePhosphotransferasesPreventionProcessProtein IsoformsProteinsProto-Oncogene Proteins c-aktRenal Cell CarcinomaResistanceResistance developmentSDZ RADSignal TransductionSignal Transduction PathwaySmall Business Innovation Research GrantSolid NeoplasmStromal CellsTestingToxic effectToxicokineticsUp-RegulationXenograft procedurealpelisibbaseclinical developmentclinically relevantcombinatorialdrug candidategene inductionin vivoinhibitorleukemiamTOR Inhibitormalignant breast neoplasmneoplastic cellnovelpatient derived xenograft modelphase 2 studypre-clinicalpreventprogramsresistance mechanismtherapeutically effectivetranscription factortranscriptional reprogrammingtranscriptomicstreatment durationtriple-negative invasive breast carcinomatumortumor growthtumor xenograft
项目摘要
Dysregulation of the PI3K/AKT/mTOR pathway is one of the most common genetic alterations in cancer, found
in more than one third of all solid tumors. Inhibitors of the key components of this pathway (mTOR, PI3K, AKT)
have been developed; some of them have been approved for breast cancer and for certain other malignancies.
However, the benefits of these inhibitors are limited by the development of resistance, which arises either through
enzymatic changes within the pathway or by the activation of compensatory signal transduction pathways or
other transcriptional changes. Suppressing transcriptional resistance mechanisms could revitalize the use of
PI3K/AKT/mTOR inhibitors, with a potentially transformative impact for many cancer patients. We propose to
combine PI3K/AKT/mTOR inhibitors with a drug candidate that selectively inhibits CDK8/19 Mediator kinase, a
regulator of transcriptional reprogramming, the key process required for the emergence of drug resistance.
CDK8/19 inhibitors (CDK8/19i) suppress the emergence of resistance to different anticancer drugs. In
preliminary studies, xenograft tumors formed by PTEN-deficient breast cancer cells were treated with mTOR
inhibitor everolimus. Although tumor growth was fully arrested for the first 7-8 weeks, all the everolimus-treated
tumors subsequently resumed their growth, indicating the development of resistance. While treatment with a
CDK8/19i as a single agent had a modest effect on tumor growth, when combined with everolimus, the CDK8/19i
fully prevented the development of resistance over 150 days of treatment. Prevention of everolimus resistance
by the CDK8/19i was associated with the counteraction of transcriptomic effects of everolimus on both tumor
and stromal cells. We hypothesize that our selective CDK8/19i preclinical drug candidate will suppress the
development of resistance not only to mTOR but also to PI3K and AKT inhibitors, extending the duration of
remission and possibly producing cures. This Phase I SBIR program will determine if the CDK8/19i prevents the
development of in vivo resistance to mTOR inhibitor everolimus, PI3Kα inhibitor alpelisib, and AKT inhibitor
capivasertib, in estrogen receptor (ER)-positive and triple-negative breast cancers. Under Aim 1, we will test the
ability of the CDK8/19i to prevent the development of in vivo resistance to everolimus, alpelisib and capivasertib
in cell-line based ER-positive and triple-negative breast cancer xenografts. Immunohistochemistry and
transcriptomic analysis will be used to characterize the tumor- and stroma-based mechanisms of in vivo
resistance to PI3K/AKT/mTOR inhibitors, which are prevented by CDK8/19 inhibition. Under Aim 2, we will
determine if the CDK8/19i will prevent the development of in vivo resistance to the combination of everolimus
and CDK8/19i in different clinically relevant patient-derived xenograft (PDX) models of ER-positive and triple-
negative breast cancers. If the CDK8/19i prevents the emergence of in vivo resistance in these models, the
future Phase II studies will be expanded to other PI3K/AKT/mTOR inhibitors, in breast cancer and other
malignancies, to identify the best drug combinations and indications for clinical development.
研究发现,PI3K/AKT/mTOR 通路失调是癌症中最常见的遗传改变之一
超过三分之一的实体瘤。该通路关键成分的抑制剂(mTOR、PI3K、AKT)
已开发;其中一些已被批准用于治疗乳腺癌和某些其他恶性肿瘤。
然而,这些抑制剂的好处受到耐药性发展的限制,这种耐药性是通过
途径内的酶促变化或通过补偿信号转导途径的激活或
其他转录变化。抑制转录抵抗机制可以重振使用
PI3K/AKT/mTOR 抑制剂,对许多癌症患者具有潜在的变革性影响。我们建议
将 PI3K/AKT/mTOR 抑制剂与选择性抑制 CDK8/19 介导激酶(一种
转录重编程的调节因子,这是耐药性出现所需的关键过程。
CDK8/19 抑制剂 (CDK8/19i) 抑制不同抗癌药物耐药性的出现。在
初步研究,用 mTOR 治疗 PTEN 缺陷型乳腺癌细胞形成的异种移植肿瘤
抑制剂依维莫司。尽管肿瘤生长在前 7-8 周内被完全抑制,但所有接受依维莫司治疗的患者
肿瘤随后恢复生长,表明耐药性的发展。治疗时用
CDK8/19i 作为单一药物对肿瘤生长具有适度的影响,当与依维莫司联合使用时,CDK8/19i
经过150天的治疗,完全阻止了耐药性的产生。预防依维莫司耐药
CDK8/19i 与依维莫司对两种肿瘤的转录组效应的抵消有关
和基质细胞。我们假设我们的选择性 CDK8/19i 临床前候选药物将抑制
不仅对 mTOR 产生耐药性,而且对 PI3K 和 AKT 抑制剂也产生耐药性,从而延长了治疗的持续时间
缓解并可能产生治愈方法。该第一阶段 SBIR 计划将确定 CDK8/19i 是否可以防止
对 mTOR 抑制剂依维莫司、PI3Kα 抑制剂 alpelisib 和 AKT 抑制剂产生体内耐药性
capivasertib,用于雌激素受体(ER)阳性和三阴性乳腺癌。在目标 1 下,我们将测试
CDK8/19i 防止体内对依维莫司、alpelisib 和 capivasertib 产生耐药性的能力
在基于细胞系的 ER 阳性和三阴性乳腺癌异种移植物中。免疫组织化学和
转录组分析将用于表征体内基于肿瘤和基质的机制
对 PI3K/AKT/mTOR 抑制剂的耐药性,可通过抑制 CDK8/19 来预防。在目标 2 下,我们将
确定 CDK8/19i 是否会阻止对依维莫司组合产生体内耐药性
和 CDK8/19i 在不同临床相关的 ER 阳性和三重患者来源的异种移植 (PDX) 模型中
阴性乳腺癌。如果 CDK8/19i 阻止这些模型中体内耐药性的出现,
未来的 II 期研究将扩展到其他 PI3K/AKT/mTOR 抑制剂,用于乳腺癌和其他癌症
恶性肿瘤,以确定临床开发的最佳药物组合和适应症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eugenia V Broude其他文献
Eugenia V Broude的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eugenia V Broude', 18)}}的其他基金
Preventing adaptive drug resistance through Mediator kinase inhibition
通过抑制介体激酶来预防适应性耐药性
- 批准号:
10518499 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Preventing adaptive drug resistance through Mediator kinase inhibition
通过抑制介体激酶来预防适应性耐药性
- 批准号:
10668528 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Potentiating targeted drugs in breast cancer via transcription-regulating kinases
通过转录调节激酶增强乳腺癌靶向药物
- 批准号:
9794385 - 财政年份:2019
- 资助金额:
$ 40万 - 项目类别:
Selective Targeting of Phosphodiesterase 11A Transcription and Catalytic Activit
磷酸二酯酶 11A 转录和催化活性的选择性靶向
- 批准号:
9061733 - 财政年份:
- 资助金额:
$ 40万 - 项目类别:
Selective Targeting of Phosphodiesterase 11A Transcription and Catalytic Activit
磷酸二酯酶 11A 转录和催化活性的选择性靶向
- 批准号:
9274311 - 财政年份:
- 资助金额:
$ 40万 - 项目类别:
相似海外基金
Deciphering the Mechanisms Underpinning Breast Cancer Cell Intravasation and Extravasation in an in vitro Vascularized System
破译体外血管系统中乳腺癌细胞内渗和外渗的机制
- 批准号:
486379 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Studentship Programs
Multiple functions of Adipsin in adipocyte-breast cancer cell interaction
Adipsin 在脂肪细胞-乳腺癌细胞相互作用中的多种功能
- 批准号:
22K15532 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of prolactin in adipocyte-breast cancer cell crosstalk
催乳素在脂肪细胞-乳腺癌细胞串扰中的作用
- 批准号:
10358133 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Deciphering the role of the Formin / Wnt-PCP axis in breast cancer cell motility and Metastasis.
破译 Formin / Wnt-PCP 轴在乳腺癌细胞运动和转移中的作用。
- 批准号:
473688 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Fellowship Programs
The roles of TRAF2 and RIP1 in breast cancer cell survival
TRAF2 和 RIP1 在乳腺癌细胞存活中的作用
- 批准号:
10363270 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
The roles of TRAF2 and RIP1 in breast cancer cell survival
TRAF2 和 RIP1 在乳腺癌细胞存活中的作用
- 批准号:
10619506 - 财政年份:2022
- 资助金额:
$ 40万 - 项目类别:
Regulation of breast cancer cell metabolism by an alternate cap-dependent mechanism of translation initiation.
通过另一种帽依赖性翻译起始机制调节乳腺癌细胞代谢。
- 批准号:
10088727 - 财政年份:2020
- 资助金额:
$ 40万 - 项目类别:
Regulation of breast cancer cell metabolism by an alternate cap-dependent mechanism of translation initiation.
通过另一种帽依赖性翻译起始机制调节乳腺癌细胞代谢。
- 批准号:
10466896 - 财政年份:2020
- 资助金额:
$ 40万 - 项目类别:
Investigating the effects of inflammation on breast cancer cell dormancy in the brain
研究炎症对大脑中乳腺癌细胞休眠的影响
- 批准号:
439809 - 财政年份:2020
- 资助金额:
$ 40万 - 项目类别:
Studentship Programs
Overcoming multi drug resistance in 3D breast cancer cell model by pH-sensitive biomimetic nanoparticles
pH敏感仿生纳米颗粒克服3D乳腺癌细胞模型中的多重耐药性
- 批准号:
20K20203 - 财政年份:2020
- 资助金额:
$ 40万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




